CDMO Idifarma has launched a new service aimed at delivering an accelerated pathway for complex drugs.
Idifarma, a contract development and manufacturing organization (CDMO), has launched a new service aimed at delivering an accelerated pathway for complex drugs. The launch was announced in a July 14, 2021 press release.
The new service, Simply to Clinic, takes drug projects from pre-formulation to clinical trial implementation guided by Idifarma’s expertise in oral standard and highly potent drugs. Customers can receive tailored services in the development, scale-up, and manufacture of the product at Idifarma’s facility in Pamplona, Spain.
“The technologies and expertise gained by Idifarma across its support of clinical trials of spray dried and oral solid dosage forms for more than 20 years provides the strong foundation needed for this service,” said Idifarma’s head of site, Alfredo Gómez, in the press release. “Innovative products and clinical trials are often complicated because of timelines, regulations, and the use of highly potent active substances. We truly believe that Simply to Clinic will provide many pharma companies with a quick and smooth entry into the challenging clinical program of new drugs. We are experienced in the problems commonly faced and will offer ourintegrated services to achieve a successful, timely, and cost-effective outcome.”
Source: Idifarma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.